Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: A meta-analysis

CMAJ. Canadian Medical Association Journal

Volumn 180, Issue 11, 2009, Pages

  Tonelli, Marcello ^a,e   Hemmelgarn, Brenda ^b   Reiman, Tony ^c   Manns, Braden ^b   Reaume, M Neil ^d   Lloyd, Anita ^a   Wiebe, Natasha ^a   Klarenbach, Scott ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADVERSE OUTCOME; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA EXTRACTION; DISEASE ASSOCIATION; DRUG USE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; META ANALYSIS; NEOPLASM; OUTCOME ASSESSMENT; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; MORTALITY; REVIEW; RISK FACTOR; STATISTICS; SURVIVAL RATE;

ANEMIA; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; HEMATINICS; HUMANS; NEOPLASMS; QUALITY OF LIFE; RISK FACTORS; SURVIVAL RATE;

EID: 67049114157     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.090470     Document Type: Article

References (76)

1. Cella D, Kallich J, McDermott A, et al. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004;15:979-986 (Pubitemid 39004357)
2. Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214-2221 (Pubitemid 32552805)
3. Savonije JH, van Groeningen CJ, van Bochove A, et al. Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: results of a multicenter randomised controlled trial. Eur J Cancer 2005;41:1560-1569 (Pubitemid 40981838)
4. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098 (Pubitemid 44749317)
5. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084 (Pubitemid 44749316)
6. Tonelli M, Lloyd A, Lee H, et al. Erythropoiesis-stimulating agents for anemia of cancer or of chemotherapy: systematic review and economic evaluation [Technology report no. 119]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2009. Available: www.cadth.ca/index.php/en/publication/ 895 (accessed 2009 May 4).
7. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999;354:1896-1900
8. Guidelines for authors of CCOHTA Health Technology Assessments reports. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessments; 2003.
9. Juni P, Altman DG, Egger M. Assessing the quality of randomised controlled trials. In: Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in health care. London (UK): BMJ Books; 2001. p. 87-108.
10. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. JAMA 1995;273:408-412
11. Jadad AR, Moore RA, Carrol D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12. (Pubitemid 26120810)
12. Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. Ann Intern Med 1996;124:485-489 (Pubitemid 26070113)
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188 (Pubitemid 17189972)
14. Higgins JPT, Thompson SG. Quanitifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558
15. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560 (Pubitemid 37088507)
16. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21:1559-1573 (Pubitemid 34746063)
17. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993;29A (Suppl 2):S2-8. (Pubitemid 23218887)
18. Cascinu S, Fedeli A, Del Ferro E, et al. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 1994;12:1058-1062 (Pubitemid 24145337)
19. Rose E, Rai K, Revicki D, et al. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO) [abstract]. Blood 1994;84(Suppl 10):526a.
20. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995;86:4446-4453
21. Osterborg A, Boogaerts MA, Cimino R, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 1996;87:2675-2682
22. Park HS, Hong DS, Lee SJ, et al. Clinical evaluation of recombinant human erythropoietin (Eprex r) in anemic cancer patients receiving chemotherapy [abstract]. Ann Oncol 1996;7.
23. A placebo-controlled study on the effect of epoetin alfa in patients with malignancy receiving chemotherapy. Raritan (NJ): Johnson & Johnson Pharmaceutical Research and Development; 2005. Available: http://clinicaltrials. gov/ct2/show/NCT00270166 (accessed 2009 Apr. 27).
24. Dammacco F, Silvestris F, Castoldi GL, et al. The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. Int J Clin Lab Res 1998;28:127-134 (Pubitemid 28320573)
25. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br J Haematol 1998;103:1070-1074
26. Kettelhack C, Hones C, Messinger D, et al. Randomized multicentre trial of the influence of recombinant human erythropoietin on intraoperative and postoperative transfusion need in anaemic patients undergoing right hemicolectomy for carcinoma. Br J Surg 1998;85:63-67 (Pubitemid 28034114)
27. Oberhoff C, Neri B, Amadori D, et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 1998;9:255-260 (Pubitemid 28186794)
28. ten Bokkel Huinink WW, de Swart CA, van Toorn DW, et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 1998;15:174-182
29. Qvist N, Boesby S, Wolff B, et al. Recombinant human erythropoietin and hemoglobin concentration at operation and during the postoperative period: reduced need for blood transfusions in patients undergoing colorectal surgery-prospective double-blind placebo-controlled study. World J Surg 1999;23:30-35 (Pubitemid 28565556)
30. Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001;113:172-179 (Pubitemid 32423318)
31. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874 (Pubitemid 32538196)
32. Huddart RA, Welch RS, Chan S, et al. A prospective randomised comparative-group evaluation of epoetin alfa for the treatment of anaemia in UK cancer patients receiving platinum-based chemotherapy. Ann Oncol 2002;13(Suppl 5):177.
33. Osterborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-2494 (Pubitemid 34525734)
34. Pronzato P, Cortesi E, van der Rijt C, et al. Early intervention with epoetin alfa in breast cancer patients undergoing chemotherapy: results of a randomized, multi-center, phase IIIb study (EPO-INT-47 Study Group). Ann Oncol 2002;13:168.
35. Thomas H, McAdam KF, Thomas RJ, et al. Early intervention with epoetin alfa for treatment of anaemia and improvement of quality of life in cancer patients undergoing myelotoxic chemotherapy. Ann Oncol 2002;13(Suppl 5):177.
36. Bamias A, Aravantinos G, Kalofonos C, et al. Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology 2003;64:102-110 (Pubitemid 36173373)
37. Boogaerts M, Coiffier B, Kainz C, et al. Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer 2003;88:988-995 (Pubitemid 36560764)
38. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260 (Pubitemid 37324251)
39. Iconomou G, Koutras A, Rigopoulos A, et al. Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial. J Pain Symptom Manage 2003;25:512-518 (Pubitemid 36629274)
40. Janinis J, Dafni U, Aravantinos G, et al. Quality of life (QoL) outcome of epoietin-alfa (EPO-A) in anemic cancer patients undergoing platinum or non-platinumbased chemotherapy: a randomized study conducted by the Hellenic Cooperative Oncology Group [abstract 3172]. Proc Am Soc Clin Oncol 2003;22:789.
41. Kosmadakis N, Messaris E, Maris A, et al. Perioperative erythropoietin administration in patients with gastrointestinal tract cancer: prospective randomized double-blind study. Ann Surg 2003;237:417-421 (Pubitemid 38176458)
42. Recasens V, Rubio-Martinez A, Gomez-Barrera M, et al. A pharmacoeconomic analysis comparing epoetin alpha vs. transfusion in patients with anemia associated with multiple myeloma [abstract 1801]. Blood 2003;102(11).
43. Chang J, Couture F, Young S, et al. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005;23:2597-2605 (Pubitemid 46179448)
44. Christodoulakis M, Tsiftsis DD, Hellenic Surgical Oncology Perioperative EPOSG. Preoperative epoetin alfa in colorectal surgery: a randomized, controlled study. Ann Surg Oncol 2005;12:718-725 (Pubitemid 41206918)
45. Mystakidou K, Kalaidopoulou O, Katsouda E, et al. Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment. Anticancer Res 2005;25:3495-3500 (Pubitemid 41105229)
46. O'Shaughnessy JA, Vukelja SJ, Holmes FA, et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 2005;5:439-446
47. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-2617 (Pubitemid 46179449)
48. Multicenter, open label study of NeoRecormon prevention and treatment for anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia. Shanghai (China): Shanghai Roche Pharmaceuticals; 2006.
49. Multicenter, open label study of NeoRecormon treatment for anemia in adult patients with multiple myeloma, low grade non-Hodgkin's lymphoma or chronic lymphocytic leukemia who have a relatively erythropoietin deficiency and are receiving antitumor chemotherapy. Shanghai (China): Shanghai Roche Pharmaceuticals; 2006.
50. Wilkinson PM, Antonopoulos M, Lahousen M, et al. Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial. Br J Cancer 2006;94:947-954
51. Machtay M, Pajak TF, Suntharalingam M, et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int J Radiat Oncol Biol Phys 2007;69:1008-1017 (Pubitemid 47625834)
52. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027-1032 (Pubitemid 46596751)
53. Aapro M, Leonard RC, Barnadas A, et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol 2008;26:592-598 (Pubitemid 351264353)
54. Strauss HG, Haensgen G, Dunst J, et al. Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer. Int J Gynecol Cancer 2008;18:515-524 (Pubitemid 351668300)
55. Thomas G, Ali S, Hoebers FJ, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008;108:317-325
56. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-1220 (Pubitemid 34993871)
57. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403. (Pubitemid 36951623)
58. Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003;39:2026-2034 (Pubitemid 37297759)
59. Taylor K, Ganly P, Charu V, et al. Randomized, double-blind, placebo-controlled study of darbepoetin alfa every 3 weeks for the treatment of chemotherapy-induced anemia [abstract]. Blood 2005;106:abstract 3556.
60. Results from a phase 3, randomized, double-blind, placebo-controlled study of darbepoetin alfa in subjects with previously untreated extensive-stage small-cell lung cancer (SCLC) treated with platinum plus etoposide chemotherapy. Thousand Oaks (CA): Amgen; 2007.
61. Charu V, Belani CP, Gill AN, et al. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial. Oncologist 2007;12:727-737 (Pubitemid 47036207)
62. Kotasek D, Canon JL, Mateos MV, et al. A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia. Curr Med Res Opin 2007;23:1387-1401 (Pubitemid 46998447)
63. Overgaard J, Hoff C, Hansen HS, et al. Randomized study of the importance on Novel Erythropoiesis Stimulating Protein (Aransep®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) - the Danish Head and Neck Cancer Group DAHANCA 10 rand [abstract 6LB]. Eur J Cancer 2007;5:7.
64. Gordon D, Nichols G, Ben-Jacob A, et al. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study. Oncologist 2008;13:715-724 (Pubitemid 351904916)
65. Smith RE Jr, Aapro MS, Ludwig H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26:1040-1050
66. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634 (Pubitemid 27387172)
67. Cella D, Eton DT, Lai JS, et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24:547-561 (Pubitemid 36120443)
68. Kallich J, McDermott A, Xu X, et al. The relationship between patient knowledge of hemoglobin levels and health-related quality of life. Qual Life Res 2006;15:57-68. (Pubitemid 43097588)
69. Kimel M, Leidy NK, Mannix S, et al. Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease. Value Health 2008;11:57-75. (Pubitemid 351160877)
70. Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int 2009; 75:15-24. Epub 2008 Aug. 27.
71. Patrick DL, Gagnon DD, Zagari MJ, et al. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003;39:335-345 (Pubitemid 36140051)
72. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008;26:132-149
73. Population by year, by province and territory. Ottawa (ON): Statistics Canada; 2007. Available: www40.statcan.gc.ca/l01/cst01/demo02a-eng.htm (updated 2007; accessed 2008 Nov. 19).
74. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in health care: meta-analysis in context. 2nd ed. London (UK): BMJ Publishing Group; 2001. p. 285-312.
75. DeMets DL, Califf RM. Lessons learned from recent cardiovascular clinical trials: Part I. Circulation 2002;106:746-751 (Pubitemid 34851937)
76. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996;50:235-242 (Pubitemid 26323718)